Mekka R. Garcia

Mekka R. Garcia

Auto-generated profile, based on publicly available information

Mekka R. Garcia

New York University Grossman School of Medicine, New York, New York

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Child Neurology Open
Verified
Journal Article
Open access
MGMekka R. Garcia
Mekka R. Garcia
LBLena Bell
Lena Bell
CMClaire Miller
Claire Miller
DSDevorah Segal
Devorah Segal
The incidence of childhood central nervous system tumors in infants is about 6 per 100 000 children. Recent studies have showed recurrent fusion of the neurotrophic tyrosine receptor kinase (NTRK) gene in 10% of non-brainstem high grade glioma in very young children suggesting an oncogenic effect of the NTRK fusion genes. In this report, we present a rare, severe case of a full-term neonate who was noted to have widely splayed sutures and a bulging fontanelle at birth who was found to have infant-type hemispheric glioma with NTRK1 fusion with course complicated by seizures refractory to medical treatment. Patient was deemed a poor surgical candidate due to the size of the mass and thus parents opted for comfort care.

6 January 2025 in Neuro-Oncology Advances
Verified
Journal Article
Open access
MGMekka R Garcia
Mekka R Garcia
MHMari Hagiwara
Mari Hagiwara
AYAnna Yaffe
Anna Yaffe
CMCarole Mitchell
Carole Mitchell
SASrivandana Akshintala
Srivandana Akshintala
MKMatthias A Karajannis
Matthias A Karajannis
Background: Axitinib is an oral multi-receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. These represent a clinically and/or preclinically validated molecular targets in vestibular schwannoma (VS). Methods: Eligible patients were age > 5 years with a clinical diagnosis of NF2-related schwannomatosis (NF2-SWN) and at least one volumetrically measurable, progressive VS. Axitinib was given continuously in 28-day cycles for up to of 12 cycles. Primary endpoint was objective volumetric response rate to axitinib, hearing response was a secondary endpoint, along with validated quality of life assessments (NFTI-QOL). Results: Twelve patients were enrolled and 8 completed 12 cycles, including 2 pediatric patients. Ten patients were evaluated for the primary endpoint, defined as ≥ 20% decrease in VS volume, with 2 volumetric responses observed; both were reached after 3 cycles and sustained during treatment. The best volumetric response was −53.9% after 9 cycles. Three hearing responses were observed, one of which was sustained during treatment. All patients experienced drug-related toxicities, the most common were diarrhea, hematuria, and skin toxicity, not exceeding grade 2, as well as hypertension, not exceeding grade 3. NFTI-QOL scores remained stable or improved during treatment. Conclusions: Axitinib therapy targeting VEGFR, PDGFR and c-KIT is feasible in this population and associated with volumetric and hearing responses in a subset of patients. However, convenience of oral administration should be balanced with respect to efficacy and safety of axitinib in comparison with other molecular-targeted therapies, including intravenous bevacizumab.

22 March 2025 in Pediatric Neurology
Verified
Journal Article
Closed access
MGMekka R. Garcia
Mekka R. Garcia
NJNora Jandhyala
Nora Jandhyala
DSDevorah Segal
Devorah Segal

17 April 2024 in Pediatric Neurology
Verified
Journal Article
Closed access
NJNora R. Jandhyala
Nora R. Jandhyala
MGMekka R. Garcia
Mekka R. Garcia
MKMonica Kim
Monica Kim
KYKaleb Yohay
Kaleb Yohay
DSDevorah Segal
Devorah Segal

17 January 2024 in Child Neurology Open
Verified
Journal Article
Open access
MGMichelle Goodman
Michelle Goodman
MGMekka R. Garcia
Mekka R. Garcia
HWHeidy Wang
Heidy Wang
MBMaria J. Borja
Maria J. Borja
CMClaire Miller
Claire Miller
DSDevorah Segal
Devorah Segal
Streptococcus pneumoniae (S. Pneumoniae) is a common cause of bacterial meningitis in the pediatric population, but rarely causes complications such as encephalitis, abscess, and seizures with the prompt initiation of proper antimicrobial therapy. In this report, we present a rare and severe case of S. Pneumoniae meningoencephalitis in a full term 6-month-old which progressed to multiple cerebral and cerebellar infarcts with concomitant cerebellar tonsillar herniation and hypercarbic respiratory failure requiring intubation and mechanical ventilation despite early initiation of antibiotics. Given the patient's clinical status and poor neurological prognosis, the family eventually opted for palliative extubation.

1 January 2024 in Child Neurology Open
Verified
Journal Article
Open access
NMNicholas Mulchan
Nicholas Mulchan
MGMekka R. Garcia
Mekka R. Garcia
JWJohn T. Wells
John T. Wells
Cobb syndrome is a rare neurocutaneous disease characterized by multiple spinal vascular anomalies and vascular skin lesions affecting the corresponding dermatome. We present a case of a 12-year-old boy with history of spinal arteriovenous malformation (AVM) extending from T4-T5 status post partial embolization 3 years ago and hyperpigmented patch overlying his thoracic back region presenting with 2 days of back pain and lower extremity numbness and weakness. He had multiple Type III AVMs within the spinal and paraspinal tissues involving the T4-T7 vertebral elements, most extensively T4 and T5. The largest aneurysm located at the confluence of the main AVM nidus was a 4 mm anterior spinal artery aneurysm, which was embolized with partial embolization of the main AVM nidus, resulting in complete aneurysm occlusion. This report provides valuable insight on the natural history, recurrence risk, and treatment options of Cobb syndrome to aid in early diagnosis and improve outcomes.